The estimated Net Worth of Susan H Tousi is at least $14.1 Million dollars as of 22 August 2023. Ms Tousi owns over 500 units of Illumina Inc stock worth over $5,682,761 and over the last 5 years she sold ILMN stock worth over $7,716,949. In addition, she makes $655,309 as Chief Commercial Officer at Illumina Inc.
Ms has made over 43 trades of the Illumina Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 500 units of ILMN stock worth $83,520 on 22 August 2023.
The largest trade she's ever made was exercising 9,969 units of Illumina Inc stock on 11 February 2020 worth over $1,244,430. On average, Ms trades about 991 units every 27 days since 2019. As of 22 August 2023 she still owns at least 45,524 units of Illumina Inc stock.
You can see the complete history of Ms Tousi stock trades at the bottom of the page.
Susan H. Tousi is the Chief Commercial Officer at Illumina Inc.
As the Chief Commercial Officer of Illumina Inc, the total compensation of Ms Tousi at Illumina Inc is $655,309. There are 10 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of $3,541,310.
Ms Tousi is 52, she's been the Chief Commercial Officer of Illumina Inc since . There are 12 older and 10 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
Susan's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley, and Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: